Home > News > Advectus and Immune Announce Nano-Pharmaceutical Project Update
September 4th, 2003
Advectus and Immune Announce Nano-Pharmaceutical Project Update
Advectus Life Sciences Inc. announced today that it has acquired an option from Immune Network Ltd. which, if exercised, would give the Company an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the "blood-brain barrier" with existing drugs.
Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014
Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014
ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014
An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014